Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

VersaBank (VBNK.T) is expected to report $0.27 for 2Q. Powered by Onclusive and Dow Jones. Advance Auto Parts Raised to Neutral From Sell by Redburn Atlantic ...

Fintel reports that on June 3, 2025, JMP Securities downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...

The health industry witnesses significant developments as Hims & Hers acquires UK startup Zava, Sanofi plans a $9.5 billion ...

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in ...

Sanofi is set to acquire Blueprint Medicines, a US-based biopharmaceutical company specialising in systemic mastocytosis.

This article summarizes recent developments in the health sector, including major acquisitions, drug trial results, and ...

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Fintel reports that on June 3, 2025, Wolfe Research downgraded their outlook for Blueprint Medicines (NasdaqGS:BPMC) from ...